Natco Pharma has announced the successful completion and submission of a certificate under SEBI regulations for the quarter ended September 30, 2025. The certificate pertains to the handling of securities received for dematerialization, ensuring compliance with depository participant regulations. The certificate was issued by Venture Capital and Corporate Investments Private Limited on October 6, 2025.
Certificate of Compliance
Natco Pharma has received a certificate confirming adherence to regulatory requirements related to depositories and participants. This announcement confirms the company’s compliance with security dematerialization processes for Q2 2025.
Key Points
The certificate, issued by Venture Capital and Corporate Investments Private Limited, confirms that securities received for dematerialization have been duly processed. This includes mutilation and cancellation after verification. The names of the depositories, National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), have been updated in the company records.
Source: BSE
